MEDIF Stock Chart & Stats
$0.06
>-$0.01(-5.26%)
At close: 4:00 PM EDT
$0.06
>-$0.01(-5.26%)
Day’s Range― - ―
52-Week Range$0.04 - $0.08
Previous CloseN/A
Volume23.34K
Average Volume (3M)35.53K
Market Cap
$20.99M
Enterprise Value$20.36
Total Cash (Recent Filing)$9.85M
Total Debt (Recent Filing)$421.00K
Price to Earnings (P/E)―
Beta-0.13
Next Earnings
Nov 16, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding427,177,150
10 Day Avg. Volume27,076
30 Day Avg. Volume35,532
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.76
Price to Sales (P/S)0.61
P/FCF Ratio-4.88
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$28.34M
Bulls Say, Bears Say
Bulls Say
Operational Profitability RecoveryThe return to quarterly profitability and consecutive positive adjusted EBITDA indicate meaningful operating recovery rather than only revenue growth. If maintained, improved earnings can strengthen internal funding, support reinvestment, and demonstrate that restructuring and margin initiatives are translating into a more viable business model.
Margin Expansion And Cost DisciplineHigher gross margins combined with substantially lower operating expenses improve the company’s path to sustainable profitability. These gains can provide resilience against pricing pressure and create operating leverage as revenue scales, although their durability depends on continued execution and favorable product mix.
Pharmaceutical Platform ValidationSuccessful controlled clinical results provide important validation for MediPharm’s pharmaceutical-style formulation capabilities and could support future product development, intellectual property, and regulated-market opportunities. This strengthens differentiation beyond commodity extraction, subject to subsequent regulatory and commercial progress.
Bears Say
Unprofitable And Cash-consuming BaseDespite recent improvement, the trailing business remains unprofitable and does not yet generate positive free cash flow. Continued cash consumption can constrain investment and increase reliance on liquidity management, making sustained positive operating earnings and cash conversion essential to complete the turnaround.
Declining Underlying RevenueA contracting trailing revenue base makes the profitability recovery more difficult to sustain because fixed costs and investment must be supported by a smaller level of sales. Durable growth will require international expansion and product initiatives to offset weakness in established channels.
Regulatory And Reimbursement ExposureThe reimbursement reduction directly lowered Canadian medical revenue and demonstrates the company’s exposure to policy decisions outside its control. Similar changes in reimbursement or prescribing rules could pressure demand, pricing, and margins, particularly while medical channels represent most of revenue.
MediPharm Labs News
MEDIF FAQ
What was MediPharm Labs’s price range in the past 12 months?
MediPharm Labs lowest stock price was $0.04 and its highest was $0.07 in the past 12 months.
What is MediPharm Labs’s market cap?
MediPharm Labs’s market cap is $20.99M.
When is MediPharm Labs’s upcoming earnings report date?
MediPharm Labs’s upcoming earnings report date is Nov 16, 2026 which is in 44 days.
How were MediPharm Labs’s earnings last quarter?
MediPharm Labs released its earnings results on Aug 13, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.002 by $0.002.
Is MediPharm Labs overvalued?
According to Wall Street analysts MediPharm Labs’s price is currently Overvalued.
Does MediPharm Labs pay dividends?
MediPharm Labs does not currently pay dividends.
What is MediPharm Labs’s EPS estimate?
MediPharm Labs’s EPS estimate is >-0.01.
How many shares outstanding does MediPharm Labs have?
MediPharm Labs has 427,177,150 shares outstanding.
What happened to MediPharm Labs’s price movement after its last earnings report?
MediPharm Labs reported an EPS of $0 in its last earnings report, beating expectations of -$0.002. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MediPharm Labs?
Currently, no hedge funds are holding shares in MEDIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MediPharm Labs
MediPharm Labs Corp. operates as a pharmaceutical entity, specializing in the creation and global commercialization of premium, pharmaceutical-grade cannabis oils, concentrates, and sophisticated derivative products. Its market reach extends across Canada, Australia, Germany, and other international territories. The company manages the full cycle from developing and processing to packaging and distributing a diverse array of cannabis extracts and advanced cannabinoid-based formulations. Furthermore, MediPharm Labs provides auxiliary services including GMP-certified flower procurement, specialized packaging, and comprehensive logistics. This enterprise was established in 2015 and has its corporate headquarters situated in Barrie, Canada.
MEDIF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong operational and financial recovery: return to profitability, highest adjusted EBITDA since 2019, robust margin expansion, meaningful sequential revenue growth driven by international markets (notably Germany), successful Phase II LiBBY clinical results validating the pharmaceutical platform, and balance sheet strength. Headwinds include a material 30% VAC reimbursement cut that reduced Canadian medical revenue, ongoing pricing pressure and competition in key markets (Germany), and broader prescribing/reimbursement uncertainties. Overall, the positive operational execution, clinical validation, and improved profitability notably outweigh the identified challenges.View all MEDIF earnings summaries